Epstein-barr virus LMP1 modulates lipid raft microdomains and the vimentin cytoskeleton for signal transduction and transformation

Journal of Virology

Volumn 87, Issue 3, 2013, Pages 1301-1311

  Meckes, David G ^b   Menaker, Nathan F ^b   Raab Traub, Nancy ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LATENT MEMBRANE PROTEIN 1; LIPID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VIMENTIN;

ANIMAL CELL; ARTICLE; CELL DISRUPTION; CELL TRANSFORMATION; CHOLESTEROL METABOLISM; CYTOSKELETON; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; FIBROBLAST; HUMAN; HUMAN CELL; LIPID ANALYSIS; LIPID RAFT; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RAT; RODENT; SIGNAL TRANSDUCTION;

EID: 84873030150     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02519-12     Document Type: Article

References (56)

1. Raab-Traub N. 2012. Novel mechanisms of EBV-induced oncogenesis. Curr. Opin. Virol. 2:453-458.
2. Raab-Traub N. 2007. EBV-induced oncogenesis, p 986-1006. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
3. Kaye KM, Izumi KM, Kieff E. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. U. S. A. 90:9150-9154.
4. Wang D, Liebowitz D, Kieff E. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831-840.
5. Mei Y-P, Zhou J-M, Wang Y, Huang H, Deng R, Feng G-K, Zeng Y-X, Zhu X-F. 2007. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBVpositive nasopharyngeal carcinoma cells. Cell Cycle 6:1379-1385.
6. Hannigan A, Wilson J. 2010. Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. Mol. Cancer 9:184.
7. Miller WE, Cheshire JL, Raab-Traub N. 1998. Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. Mol. Cell. Biol. 18:2835-2844.
8. Mosialos G, Birkenbacht M, Yalamanchill R, Van Arsdale T, Ware C, Kleff E. 1995. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80: 389-399.
9. Eliopoulos AG, Young LS. 1998. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731-1742.
10. Mainou BA, Everly DN, Raab-Traub N. 2005. Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene 24:6917-6924.
11. Paine E, Scheinman RI, Baldwin AS, Raab-Traub N. 1995. Expression of LMP1 in epithelial cells leads to the activation of a select subset of NF-κB/ Rel family proteins. J. Virol. 69:4572-4576.
12. Roberts ML, Cooper NR. 1998. Activation of a Ras/MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 240:93-99.
13. Kung C-P, Meckes DG, Raab-Traub N. 2011. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKC. J. Virol. 85: 4399-4408.
14. Yasui T, Luftig M, Soni V, Kieff E. 2004. Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. Proc. Natl. Acad. Sci. U. S. A. 101:278-283.
15. Pioche-Durieu C, Keryer C, Souquère S, Bosq J, Faigle W, Loew D, Hirashima M, Nishi N, Middeldorp J, Busson P. 2005. In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J. Virol. 79:13326 -13337.
16. Katano H, Pesnicak L, Cohen JI. 2004. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc. Natl. Acad. Sci. U. S. A. 101: 4960-4965.
17. Lingwood D, Simons K. 2010. Lipid rafts as a membrane-organizing principle. Science 327:46-50.
18. Staubach S, Hanisch F-G. 2011. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expt. Rev. Proteomics 8:263-277.
19. Everly DN, Mainou BA, Raab-Traub N. 2004. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J. Virol. 78:13470-13478.
20. Fries KL, Miller WE, Raab-Traub N. 1996. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J. Virol. 70:8653-8659.
21. Shair KHY, Schnegg CI, Raab-Traub N. 2008. EBV latent membrane protein 1 effects on plakoglobin, cell growth, and migration. Cancer Res. 68:6997-7005.
22. Birkenbach M, Liebowitz D, Wang F, Sample J, Kieff E. 1989. Epstein- Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines. J. Virol. 63:4079-4084.
23. Ivaska J, Pallari Nevo H-MJ, Eriksson JE. 2007. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res. 313: 2050-2062.
24. Runembert I, Queffeulou G, Federici P, Vrtovsnik F, Colucci-Guyon E, Babinet C, Briand P, Trugnan G, Friedlander G, Terzi F. 2002. Vimentin affects localization and activity of sodium-glucose cotransporter SGLT1 in membrane rafts. J. Cell Sci. 115:713-724.
25. Sprenger RR, Fontijn RD, van Marle J, Pannekoek H, Horrevoets AJ. 2006. Spatial segregation of transport and signalling functions between human endothelial caveolae and lipid raft proteomes. Biochem. J. 400: 401-410.
26. Liebowitz D, Kopan R, Fuchs E, Sample J, Kieff E. 1987. An Epstein- Barr virus transforming protein associates with vimentin in lymphocytes. Mol. Cell Biol. 7:2299-2308.
27. Whipple RA, Balzer EM, Cho EH, Matrone MA, Yoon JR, Martin SS. 2008. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res. 68:5678-5688.
28. Kim KB, Lee JS, Ko YG. 2008. The isolation of detergent-resistant lipid rafts for two-dimensional electrophoresis. Methods Mol. Biol. 424:413-422.
29. Higuchi M, Izumi KM, Kieff E. 2001. Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc. Natl. Acad. Sci. U. S. A. 98:4675-4680.
30. Lam N, Sugden B. 2003. LMP1, a viral relative of the TNF receptor family, signals principally from intracellular compartments.EMBOJ. 22:3027-3038.
31. Ardila-Osorio H, Pioche-Durieu C, Puvion-Dutilleul F, Clausse B, Wiels J, Miller W, Raab-Traub N, Busson P. 2005. TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1. Int. J. Cancer 113:267-275.
32. Brown DA. 2001. Isolation and use of rafts, p 51:11.10.1-11.10.23. In Current protocols in immunology. John Wiley & Sons, Inc., New York, NY.
33. Chabanel A, Flamm M, Sung KL, Lee MM, Schachter D, Chien S. 1983. Influence of cholesterol content on red cell membrane viscoelasticity and fluidity. Biophys. J. 44 171-176
34. Lei B, Morris DP, Smith MP, Schwinn DA. 2009. Lipid rafts constrain basal α1A-adrenergic receptor signaling by maintaining receptor in an inactive conformation. Cell Signal. 21:1532-1539.
35. Furuchi T, Anderson RGW. 1998. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J. Biol. Chem. 273:21099-21104.
36. 3-adrenergic receptor activation of ERK MAP kinase and lipolysis. J. Biol. Chem. 282:9244-9250.
37. Perlson E, Michaelevski I, Kowalsman N, Ben-Yaakov K, Shaked M, Seger R, Eisenstein M, Fainzilber M. 2006. Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J. Mol. Biol. 364:938-944.
38. Calay D, Vind-Kezunovic D, Frankart A, Lambert S, Poumay Y, Gniadecki R. 2010. Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J. Invest. Dermatol. 130:1136-1145.
39. Li YC, Park MJ, Ye S-KKim C-WKim Y-N. 2006. Elevated levels of cholesterol- rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 168:1107-1118.
40. Lasserre R, Guo XJ, Conchonaud F, Hamon Y, Hawchar O, Bernard AM, Soudja SM, Lenne PF, Rigneault H, Olive D, Bismuth G, Nunes JA, Payrastre B, Marguet D, He HT. 2008. Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat. Chem. Biol. 4:538-547.
41. Fedida-Metula S, Elhyany S, Tsory S, Segal S, Hershfinkel M, Sekler I, Fishman D. 2008. Targeting lipid rafts inhibits protein kinase B by disrupting calcium homeostasis and attenuates malignant properties of melanoma cells. Carcinogenesis 29:1546-1554.
42. Dawson CW, Tramountanis G, Eliopoulos AG, Young LS. 2003. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J. Biol. Chem. 278:3694-3704.
43. Ha YJ, Lee JR. 2004. Role of TNF receptor-associated factor 3 in the CD40 signaling by production of reactive oxygen species through association with p40phox, a cytosolic subunit of nicotinamide adenine dinucleotide phosphate oxidase. J. Immunol. 172:231-239.
44. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G. 1996. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kB activation. Mol. Cell. Biol. 16:7098-7108.
45. Owen PJ, Johnson GD, Lord JM. 1996. Protein Kinase C-δ Associates with vimentin intermediate filaments in differentiated HL60 cells. Exp. Cell Res. 225:366-373.
46. Chen Y-W, Lang ML, Wade WF. 2004. Protein kinase C-α and δ-are required for FcαR (CD89) trafficking to MHC class II compartments and FcαR-mediated antigen presentation. Traffic 5:577-594.
47. Ivaska J, Whelan RDH, Watson R, Parker PJ. 2002. PKCe controls the traffic of β integrins in motile cells. EMBO J. 21:3608-3619.
48. Ivaska J, Vuoriluoto K, Huovinen T, Izawa I, Inagaki M, Parker PJ. 2005. PKCe-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J. 24:3834-3845.
49. Vockerodt M, Tesch H, Kube D. 2001. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFκB pathway. Genes Immun. 2:433-441.
50. Walter J, Schirrmacher V, Mosier D. 1995. Induction of CD44 expression by the Epstein-Barr virus latent membrane protein LMP1 is associated with lymphoma dissemination. Intern. J. Cancer 61:363-369.
51. Shair KHY, Schnegg CI, Raab-Traub N. 2009. Epstein-Barr virus latent membrane protein-1 effects on junctional plakoglobin and induction of a cadherin switch. Cancer Res. 69:5734-5742.
52. Buschow SI, van Balkom BWM, Aalberts M, Heck AJR, Wauben M, Stoorvogel W. 2010. MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunol. Cell Biol. 88:851-856.
53. Meckes DG, Raab-Traub N. 2011. Microvesicles and viral infection. J. Virol. 85:12844-12854.
54. Meckes DG, Shair KHY, Marquitz AR, Kung Edwards C-PRH, Raab- Traub N. 2010. Human tumor virus utilizes exosomes for intercellular communication. Proc. Natl. Acad. Sci. U. S. A. 107:20370-20375.
55. Verweij FJ, van Eijndhoven MAJ, Hopmans ES, Vendrig T, Wurdinger T, Cahir-McFarland E, Kieff E, Geerts D, van der Kant R, Neefjes J, Middeldorp JM, Pegtel DM. 2011. LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activation. EMBO J. 30:2115-2129.
56. Lee J, Sugden B. 2007. A membrane leucine heptad contributes to trafficking, signaling, and transformation by latent membrane protein 1. J. Virol. 81:9121-9130.